Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA-Sponsor Conferences-Reference-Cited by-同舟云学术

Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA-Sponsor Conferences

Published:1997-07 Issue:3 Volume:31 Page:771-788
ISSN:0092-8615
Container-title:Drug Information Journal
language:en
Short-container-title:Drug Information J

Author:

DiMasi Joseph A.,Manocchia Michael

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug Guides,Pharmacology (nursing)

Link

http://link.springer.com/content/pdf/10.1177/009286159703100319.pdf

Reference32 articles.

1. Clinton B, Gore A. National Performance Review: Reinventing Government. Washington, DC: The White House; 1995.

2. FDA Regulatory Reform: A Proposal by the Biotechnology Industry Organization. Concept Paper: 2/27/ 95. BIO, Washington DC, 1995.

3. Epstein RA, Lenard TM, Miller HI, Tollison RD, Viscusi WK, Wardell WM. Advancing medical innovation: health, safety and the role of government in the 21st century. Washington, DC: The Progress and Freedom Foundation; February 7, 1996.

4. Clinton B, Gore A. Reinventing the Regulation of Cancer Drugs. Washington, DC: The White House; March 29, 1996.

5. The Patient is Waiting. Washington, DC: Pharmaceutical Research and Manufacturers of America; May 1996.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory review of new product innovation: Conceptual clarity and future research directions;Technological Forecasting and Social Change;2022-02

2. Pre—Investigational New Drug Meetings With the FDA: Evaluation of Meeting Content and Characteristics of Applications for New Drug and Biologic Products;Therapeutic Innovation & Regulatory Science;2015-05

3. Future Prospects of the Pharmaceutical Industry and its Regulation in the USA;The Textbook of Pharmaceutical Medicine;2013-04-25

4. Factors Associated with Multiple FDA Review Cycles and Approval Phase Times;Drug Information Journal;2009-03

5. US and European regulatory initiatives to improve R&D performance;Expert Opinion on Drug Discovery;2006-06